

EDITORIAL



Sanofi-Cell Research outstanding paper award of 2020

© CEMCS, CAS 2021

Cell Research (2021) 31:1225; <https://doi.org/10.1038/s41422-021-00593-8>


This is an exciting moment for us to announce the winners of the 2020 Sanofi-Cell Research Outstanding Review Article Award: Dr Eran Elinav,¹ for his review paper entitled “Interaction between microbiota and immunity in health and disease”; and the Sanofi-Cell Research Outstanding Research Article Award: Drs Lu Lu, Shibo Jiang, Yun Zhu,² for their research paper entitled “Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion”; Drs Hongkui Deng and Tuoping Luo,³ for their research paper entitled “Elimination of senescent cells by β -galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice”. The award consists of a prize of ¥25,000 for the Outstanding Review Article Award and ¥40,000 for the Outstanding Research Article Award sponsored by Sanofi.

Let us take a brief look at these three excellent works. In the award-winning review article from Dr Elinav and colleagues,¹ published in the June 2020 issue, the authors systematically discussed host immune-microbiome interactions and their potential effects on human health and disease risk, providing a comprehensive picture of the microbiota-immunity realm. In the first award-winning research article, published in the April 2020 issue, Drs Lu Lu, Shibo Jiang, Yun Zhu and colleagues,² reported a pan-coronavirus fusion inhibitor that showed potent inhibition of infection of several human coronaviruses, and exhibited both prophylactic and therapeutic efficacy in mouse model. This is a timely finding on the potential treatments against SARS-CoV-2 infection in the very early phase of COVID-19 outbreak. In the second award-winning research article, published in the July 2020 issue, Drs Deng, Luo and colleagues³ designed and developed a novel compound based on the increased activity of lysosomal β -galactosidase, which could eliminate mouse and human senescent cells, and restore physical function in aged mice. Clearing senescent cells is a promising approach to treat age-related diseases and improve physical function. This work opens a new avenue for treating aging-associated diseases.

Please join us to congratulate Dr Elinav, Drs Deng and Luo, Drs Lu, Jiang and Zhu on their winning of the 2020 Sanofi-Cell Research Outstanding Paper Award.



Dr Eran Elinav



Dr Hongkui Deng




Dr Tuoping Luo



Dr Lu Lu



Dr Shibo Jiang



Dr Yun Zhu

Cell Research Editorial Team¹

¹Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.

Correspondence: cellres@sibcb.ac.cn

REFERENCES

1. Zheng, D. et al. *Cell Res.* **30**, 492–506 (2020).
2. Xia, S. et al. *Cell Res.* **30**, 343–355 (2020).
3. Cai, Y. et al. *Cell Res.* **30**, 574–589 (2020).